<code id='0DD551B837'></code><style id='0DD551B837'></style>

<acronym id='0DD551B837'></acronym>

<center id='0DD551B837'><center id='0DD551B837'><tfoot id='0DD551B837'></tfoot></center><abbr id='0DD551B837'><dir id='0DD551B837'><tfoot id='0DD551B837'></tfoot><noframes id='0DD551B837'>

<optgroup id='0DD551B837'><strike id='0DD551B837'><sup id='0DD551B837'></sup></strike><code id='0DD551B837'></code></optgroup>

<b id='0DD551B837'><label id='0DD551B837'><select id='0DD551B837'><dt id='0DD551B837'><span id='0DD551B837'></span></dt></select></label></b><u id='0DD551B837'></u>

~~<i id='0DD551B837'><strike id='0DD551B837'><tt id='0DD551B837'><pre id='0DD551B837'></pre></tt></strike></i>~~

Home» comprehensive» knowledge

knowledge

knowledge

author：focus 2025-10-01 13:04:17 Page View：541

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

advertisement

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Do digital therapeutics have a future in medicine?
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

focus

ChatGPT in medicine: STAT answers readers' burning questions

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

BioMarin wins approval for gene therapy to treat hemophilia A

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Time to name cancers by genetics, not organ of origin, expert says

Treatmentsforlungcancercanvarydependingonspecificmutation.Anoncologistarguesthecancersshouldhavediff

read more